Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label 3-cohort study of crizanlizumab alone or with nivolumab in glioblastoma and melanoma brain metastases
MOH_2023-05-09_012621Phase 2Recruiting
- Sponsor
- דוקטור רוני שפירא-פרומר
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of crizanlizumab and nivolumab in glioblastoma (GBM), melanoma and brain metastases (3 arms), sponsored by דוקטור רוני שפירא-פרומר. Primary endpoint: Safety and tolerability. Started Mar 2023; status: recruiting.
02
Drugs
crizanlizumabnivolumab
03
Conditions
glioblastoma (GBM)melanomabrain metastases
Beyond the preview
Go deeper on MOH_2023-05-09_012621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-05-09_012621.